Urothelial Cancer Current Events | Urothelial Cancer News
|
| Page
1 of
80 |
1581 Results |
|
|
|
Sort By:
Page Views | Date |
Bladder cells feel stretch
Japanese research group led by Prof. Makoto Tominaga and Dr. Takaaki Sokabe (National Institute for Physiological Sciences: NIPS), and Prof. Masayuki Takeda, Dr. Isao Araki and Dr. Tsutomu Mochizuki (Yamanashi Univ.), found that bladder urothelial cells have a sensor for stretch stimulation. view more (2009-08-07)
Robotic approach to urothelial cancer of the kidney proves to be beneficial for patients
Robotic trained surgeons at Fox Chase Cancer Center in Philadelphia presented a new and novel approach to surgically treat urothelial cancer (in the lining of the bladder or kidney) today at the American Urological Association's Annual Meeting. view more (2009-04-27)
Bladder cancer detected via amplified gene in cells found in urine
Counting the copies of a specific gene in cells gathered from a urine sample may provide a simple, noninvasive way to detect bladder cancer, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute. view more (2008-09-24)
Jefferson, Ohio State team find gene signature profile for metastasis
A common signature of tiny, specific pieces of non-coding genetic material known as microRNAs (miRNAs) may be directly involved in the spread of cancer to other parts of the body. view more (2008-06-02)
Different method of evaluating the urinary tract system reduces radiation dose
The split-bolus (cross sectional imaging) MDCT urography technique reduces both radiation dose and number of images produced, according to a recent study conducted by radiologists from Stanford University School of Medicine in Stanford, CA and VA Palo Alto Health Care System in Palo Alto, CA. view more (2007-08-29)
Who gets cancer treatment, and who completes it?
Cancer treatment is now very effective in many cases, yet not all patients with cancer are referred and not all complete their treatment programme. This has puzzled cancer specialists who have wondered if psychological factors might influence their decision and has led to research carried out by Dr Stan Lindsay from the Institute of Psychiatry in... view more... (2002-11-13)
Comment from Professor Nick Lemoine, Director of Imperial Cancer Research Fund's Molecular Oncology Unit at the Hammersmith Hospital, in response to US research* that has linked breast cancer to a virus:
Comment from Professor Nick Lemoine, Director of Imperial Cancer Research Fund's Molecular Oncology Unit at the Hammersmith Hospital, in response to US research* that has linked breast cancer to a virus: view more (1999-08-11)
PROSTATE CANCER SERIES (p 859)
A four-week series about prostate cancer-the third most common cancer in men worldwide, and the leading male cancer in Europe and North America-begins in this week's issue of THE LANCET. The first article, by Henrik Grönberg of Umea University, Sweden, assesses the epidemiology of prostate cancer, and examines the impact of genetic and... view more... (2003-03-05)
Family history of breast cancer does not increase risk of womb cancer
A family history of breast cancer does not increase a woman`s chances of developing womb cancer, finds a 20-year study in the Journal of Medical Genetics. Cancers of the lining of the womb (endometrium) and breast share some of the same reproductive, hormonal, and lifestyle risk factors. The evidence for a genetic link between the two types of... view more... (2002-11-01)
Breast cancer drug receives FDA approval
A new use for the breast cancer drug Herceptin was approved by the FDA yesterday, a move that means more treatment options for the 25 percent of breast cancer patients with early-stage HER-2 positive breast cancer. view more (2006-11-20)
Chemotherapy and tamoxifen reduce risk of second breast cancer
Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute. The risk reduction persisted for at least 10 and 5 years, respectively. view more (2007-12-26)
Women smokers have higher risk of lung cancer than men smokers, though lower lung cancer death rate
Women who smoke appear to be more susceptible to lung cancer than men who smoke, though women smokers have a lower rate of lung cancer-related death. view more (2006-07-12)
Increased ovarian cancer risk not found in women with breast cancer family history
Women with a strong family history of breast cancer but who don't have breast cancer genetic mutations can now be reassured that they are not at increased risk for ovarian cancer. view more (2005-09-21)
Women without regular medical care at increased risk of ovarian cancer
In North America, ovarian cancer is the second most common gynecological cancer and is the leading cause of death among women with gynecological cancer. The high mortality is in part due to the difficulty of detecting and diagnosing this condition at an early stage. view more (2007-03-27)
Breast asymmetry predicts breast cancer
Women who go on to develop breast cancer tend to have breasts that are less symmetrical than women who don't develop the cancer. view more (2006-03-20)
New gene silencing therapy for cervical cancer
Researchers at The University of Queensland's (UQ) Centre for Immunology and Cancer Research (CICR), based at the Princess Alexandra Hospital, have pioneered a new approach for the treatment of cervical cancer. view more (2005-11-17)
Increased levels of Muellerian-inhibiting substance could mean greater breast cancer risk
Women with increased levels of Müllerian inhibiting substance (MIS), best known for regulating in utero sexual differentiation in boys, may be at a greater risk for breast cancer. view more (2009-10-12)
Media Registration: Europe`s largest breast cancer conference to be held in Barcelona
3rd European Breast Cancer Conference (EBCC-3) Palau de Congressos de Catalunya, Barcelona, Spain 19-23 March 2002 ABOUT EBCC-3"¦ * More than 3000 clinicians, scientists and patient advocates will attend. * Presentations will review new developments in molecular biology, epidemiology, prevention, diagnosis, treatment, psycho-social... view more... (2001-12-04)
Cancer Research UK supports additional TroVax phase II trial in colorectal cancer
Oxford BioMedica announced today that Cancer Research UK (CRUK) has agreed to conduct and sponsor an open label Phase II trial with Oxford BioMedica's leading cancer immunotherapy product, TroVax®, in colorectal cancer patients who have liver metastases. The decision by CRUK follows extensive review of the successful Phase I/II data of TroVax... view more... (2003-08-28)
Estrogen-progestin menopausal hormone therapy and risk of lobular and tubular breast cancer
Estrogen-progestin menopausal hormone therapy is associated with a more than two-fold higher relative risk of developing lobular cancer or tubular cancer than of developing ductal cancer. view more (2006-02-17)
|
|
| Page
1 of
80 |
1581 Results |
|
|
|
Sort By:
Page Views | Date |
|
